TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-κB Dependent Induction of cFLIPL

Josep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al. · 2010

Read TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-κB Dependent Induction of cFLIPL by Josep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008620.txt.

Description

Josep Maria Lluis and co-authors study cell survival signaling in a 2010 PLOS ONE paper. TRAIL is known as a death ligand in the TNF superfamily. It binds receptors bearing death domains and can kill tumor cells. It can also activate NF-kappaB, a survival pathway. The team study mouse fibroblasts treated with TRAIL. They ask if a kinase called TAK1 is required for their survival. TAK1 sits upstream of NF-kappaB activation.

They find TAK1 is required for survival of fibroblasts treated with TRAIL. It acts by NF-kappaB dependent induction of cFLIPL, a death blocker. Removing TAK1 tips TRAIL from survival signaling toward death. That balance matters for TRAIL-based cancer therapies under development.

Catalog record

CREATORJosep Maria Lluis, Ulrich Nachbur, Wendy Diane Cook et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008620

Browse the full library · About the Tower of Babel